Nanofactories for Controlled Synthesis and Delivery of Nucleoside Analogue Therapeutics

Kourosh H. Ebrahimi

doi:10.1002/cbic.202000382

Nanofactories for Controlled Synthesis and Delivery of Nucleoside Analogue Therapeutics

Kourosh H. Ebrahimi^*

^*Corresponding author for this work

Institute of Pharmaceutical Science

Research output: Contribution to journal › Comment/debate › peer-review

1 Citation (Scopus)

Abstract

The ultimate nanomedicine will be a cell-like machinery capable of reaching a specific target in the body and performing a desired therapeutic action in a controlled fashion. To make such machinery a reality, we need to combine fundamental knowledge and technological developments in different areas including polymer chemistry, biology, enzymology, and biochemical engineering. In this viewpoint, I put forward my vision of creating a nanofactory as a step towards developing cell-like nanomedicines. To make the proposed nanofactory a reality there are many challenges ahead. I propose plausible solutions to address some of the main challenges.

Original language	English
Pages (from-to)	3186-3188
Number of pages	3
Journal	Chembiochem : a European journal of chemical biology
Volume	21
Issue number	22
DOIs	https://doi.org/10.1002/cbic.202000382
Publication status	Published - 16 Nov 2020

Keywords

Animals
Drug Delivery Systems
Humans
Nanomedicine
Nucleosides/chemical synthesis

Access to Document

10.1002/cbic.202000382

Cite this

@article{eb27d8bef01a4c039d583b8a0f271bbb,

title = "Nanofactories for Controlled Synthesis and Delivery of Nucleoside Analogue Therapeutics",

abstract = "The ultimate nanomedicine will be a cell-like machinery capable of reaching a specific target in the body and performing a desired therapeutic action in a controlled fashion. To make such machinery a reality, we need to combine fundamental knowledge and technological developments in different areas including polymer chemistry, biology, enzymology, and biochemical engineering. In this viewpoint, I put forward my vision of creating a nanofactory as a step towards developing cell-like nanomedicines. To make the proposed nanofactory a reality there are many challenges ahead. I propose plausible solutions to address some of the main challenges.",

keywords = "Animals, Drug Delivery Systems, Humans, Nanomedicine, Nucleosides/chemical synthesis",

author = "{H. Ebrahimi}, Kourosh",

note = "{\textcopyright} 2020 Wiley-VCH GmbH.",

year = "2020",

month = nov,

day = "16",

doi = "10.1002/cbic.202000382",

language = "English",

volume = "21",

pages = "3186--3188",

journal = "Chembiochem : a European journal of chemical biology",

issn = "1439-4227",

publisher = "Wiley-VCH Verlag",

number = "22",

}

TY - JOUR

T1 - Nanofactories for Controlled Synthesis and Delivery of Nucleoside Analogue Therapeutics

AU - H. Ebrahimi, Kourosh

PY - 2020/11/16

Y1 - 2020/11/16

N2 - The ultimate nanomedicine will be a cell-like machinery capable of reaching a specific target in the body and performing a desired therapeutic action in a controlled fashion. To make such machinery a reality, we need to combine fundamental knowledge and technological developments in different areas including polymer chemistry, biology, enzymology, and biochemical engineering. In this viewpoint, I put forward my vision of creating a nanofactory as a step towards developing cell-like nanomedicines. To make the proposed nanofactory a reality there are many challenges ahead. I propose plausible solutions to address some of the main challenges.

AB - The ultimate nanomedicine will be a cell-like machinery capable of reaching a specific target in the body and performing a desired therapeutic action in a controlled fashion. To make such machinery a reality, we need to combine fundamental knowledge and technological developments in different areas including polymer chemistry, biology, enzymology, and biochemical engineering. In this viewpoint, I put forward my vision of creating a nanofactory as a step towards developing cell-like nanomedicines. To make the proposed nanofactory a reality there are many challenges ahead. I propose plausible solutions to address some of the main challenges.

KW - Animals

KW - Drug Delivery Systems

KW - Humans

KW - Nanomedicine

KW - Nucleosides/chemical synthesis

U2 - 10.1002/cbic.202000382

DO - 10.1002/cbic.202000382

M3 - Comment/debate

C2 - 32964558

SN - 1439-4227

VL - 21

SP - 3186

EP - 3188

JO - Chembiochem : a European journal of chemical biology

JF - Chembiochem : a European journal of chemical biology

IS - 22

ER -

Nanofactories for Controlled Synthesis and Delivery of Nucleoside Analogue Therapeutics

Abstract

Keywords

Access to Document

Fingerprint

Cite this